Miller-Patterson, Cameron http://orcid.org/0000-0003-2885-0907
Hsu, Jesse Y. http://orcid.org/0000-0002-1522-6534
Chahine, Lana M. http://orcid.org/0000-0003-2521-7196
Morley, James F.
Willis, Allison W. http://orcid.org/0000-0001-5724-7192
Funding for this research was provided by:
National Institute of General Medical Sciences (GM075766)
Article History
Received: 28 May 2022
Accepted: 22 August 2022
First Online: 3 September 2022
Declarations
:
: Dr. Miller-Patterson has nothing to disclose. Dr. Hsu has received personal compensation in the range of $10,000–$49,999 for serving as Editor, Associate Editor, or Editorial Advisory Board Member for National Kidney Foundation and Public Library of Science. Dr. Chahine has received personal compensation in the range of $500–$4,999 for serving as a consultant for Gray Matters Technology. Dr. Chahine has received research support from University of Pittsburgh Medical Center, Michael J. Fox Foundation, and Biogen/Parkinson Study Group. Dr. Chahine has received publishing royalties from a publication relating to health care. Dr. Morley has nothing to disclose. Dr. Willis has received personal compensation in the range of $0–$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Pharmacoepidemiology and Drug Safety. Dr. Willis has received research support from National Institutes of Health, National Institute on Aging, Biogen, Parkinson Foundation, and Arcadia.
: Each Parkinson’s Progression Markers Initiative site received approval from an ethics committee on human experimentation in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments before study initiation and obtained written informed consent from each study participant.